SUMMARY Forty five patients with acute ulcerative colitis were randomly allocated to receive (a) sulphasalazine, (b) levamisole, or (c) a combination of sulphasalazine and levamisole. Each group contained 15 patients. The ulcerative colitis activity index (UCAI), the remission and relapse rates were compared at three monthly intervals for one year. The UCAI fell in each group. Detailed analysis of all clinical and biochemical parameters used for estimation of UCAI showed that the only difference was in patients receiving combined therapy who continued to have a raised ESR and platelet count. Fewer patients, however, went into remission on levamisole therapy (46.6%) compared with the other two groups (66.6%). The cumulative relapse rate was 20% for those receiving levamisole compared with 6-6% in the other groups. Side effects were observed in 20% of patients receiving levamisole, 26% On entry into the trial, patients were randomly allocated to one of the three groups: (a) sulphasalazine, 6 g daily until remission occurred, followed by 3-4 g daily as maintenance therapy, (b) levamisole 150 mg orally twice a week for the first two weeks and then once a week thereafter, (c) levamisole plus sulphasalazine in the doses used in groups (a) and (b). Allocation was performed using a table of random numbers. 534 Each patient was given a diary card on which to record the daily number of stools, the presence or absence of blood, the degree of abdominal pain, temperature and body weight. The UCAI was measured on the first visit and every three months during the year of treatment. At each visit, sigmoid- Figure 1 shows the UCAI for each group on entry into the trial and at each three month period during the subsequent year. At each time interval there were no significant differences between the groups. For all patients there was a fall in the UCAI during treatment between the groups. For all patients there was a fall in the UCAI during treatment regardless of which therapeutic regimen they were receiving. F'igure 2a shows that the daily number of stools each patient passed progressively diminished during treatment and there was a small rise in body weight during the trial period. No differences were seen between groups. Figure 2b shows The sigmoidoscopic appearances are shown in Table 3 .
REMISSION AND RELAPSE RATES
For groups (a) and (c), 10 patients (66.6%) in each group went into remission on treatment compared with seven patients (46.6%) in the levamisole treated group (group b). This difference was not significant. In group (b), three patients (20%) relapsed compared with only one patient (6.6%) in each other group. This difference was not significant.
SIDE EFFECTS
Side effects were observed in six patients from group (c) ( Table 4 ). In groups (a) and (b), side-effects were observed in three and four patients respectively. Two patients in group (b) and two in The comparatively low dose of levamisole used in this trial has been shown to be associated with few side effects although its immunostimulatory properties are maintained.24 Twenty six per cent of patients receiving levamisole, however, developed side effects which is similar to that reported in other series using a higher dosage.8 Thus no reduction of side effects was seen using the lower dose. In conclusion, the results of this trial suggest that levamisole is of little benefit in the management of ulcerative colitis. They may also suggest that the pathogenesis of the disease is not a result of an impaired immune response. 
